Mary A. O’Neal, MD, FAAN, Guest Editor
Assistant Professor of Neurology, Harvard Medical School; Director, Women’s Neurology Program; Ambulatory Director of Neurology; Director, Neurosciences Clinic, Brigham and Women’s Hospital, Boston, Massachusetts

*Relationship Disclosure: Dr O’Neal serves as a consultant for Teladoc Health, Inc; receives publishing royalties from Oxford University Press and Springer Nature Switzerland AG; and has served as an expert consultant for CRICO medical malpractice insurers.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr O’Neal reports no disclosure.

Riley M. Bove, MD

Associate Professor of Neurology, University of California San Francisco, San Francisco, California

*Relationship Disclosure: Dr Bove has served as a consultant for Alexion Pharmaceuticals, Inc; Biogen; EMD Serono; F. Hoffman-La Roche Ltd; Momenta Pharmaceuticals, Inc; Novartis AG; and Sanofi Genzyme and has received research/grant support from Biogen, F. Hoffman-La Roche Ltd, and Novartis AG.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Bove discusses the unlabeled/investigational use of rituximab for multiple sclerosis and neuromyelitis optica spectrum disorder and the unlabeled/investigational use of immunosuppressives for neuromyelitis optica spectrum disorder.

Karissa L. Gable, MD

Associate Professor of Neurology, Duke University Medical Center, Durham, North Carolina

*Relationship Disclosure: Dr Gable serves as a consultant for Apellis Pharmaceuticals Inc and Medscape and has received research/grant support from the American Neuromuscular Foundation and GBS/CIDP Foundation International.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Gable reports no disclosure.

Na Tosha N. Gatson, MD, PhD, FAAN

Associate Professor of Medicine and Neurology; Medical Director, Neuro-Oncology, Banner MD Anderson Cancer Center, University of Arizona College of Medicine, Phoenix, Arizona; Adjunct Associate Professor of Medicine, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania

**Relationship Disclosure: Dr Gatson has served as an advisory board consultant for Novocure GmbH.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Gatson reports no disclosure.

Maria K. Houtchens,MD

Associate Professor of Neurology, Harvard Medical School; Director, Clinical Care; Director, Women’s Health Program; Associate Director, Women’s Neurology Fellowship, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital, Boston, Massachusetts

*Relationship Disclosure: Dr Houtchens has served as a consultant for Alexion Pharmaceuticals, Inc; Biogen; EMD Serono; F. Hoffman-La Roche Ltd; Novartis AG; and Sanofi Genzyme and has received research/grant support from Biogen, F. Hoffman-La Roche Ltd, and Sanofi Genzyme. Dr. Houtchens has provided legal expert testimony on motor-vehicle accidents in patients with neurologic illness and has served as an expert witness in medical malpractice cases.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Houtchens discusses the unlabeled/investigational use of rituximab for multiple sclerosis and neuromyelitis optica spectrum disorder and the unlabeled/investigational use of immunosuppressives for neuromyelitis optica spectrum disorder.

Joseph S. Kass, MD, JD, FAAN

Professor of Neurology, Psychiatry and Medical Ethics, Baylor College of Medicine, Houston, Texas

*Relationship Disclosure: Dr Kass serves as associate editor of medicolegal issues for Continuum, as a neurology section editor of Ferri’s Clinical Advisor for Elsevier, and as co-editor of Neurology Secrets, Sixth Edition and has served as an associate editor for Continuum Audio. Dr Kass serves as a principal investigator for clinical trials for Alzheimer disease from Biogen; Eisai Co, Ltd; Lilly; the National Institutes of Health; Novartis AG; Novo Nordisk; and Roche Diagnostics.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Kass reports no disclosure.

Yi Li, MD, PhD

Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford University, Palo Alto, California

*Relationship Disclosure: Dr Li reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Li reports no disclosure.

Janice M. Massey, MD, FAAN

Professor and Executive Vice-Chair of Neurology, Duke University Medical Center, Durham, North Carolina

*Relationship Disclosure: Dr Massey serves on the editorial board of Clinical Neurophysiology Practice as an investigator for UCB SA/Ra Pharmaceuticals, on a scientific advisory board for Argenx, and on a scientific advisory committee for Momenta Pharmaceuticals, Inc. Dr Massey has received research/grant support from Revance Therapeutics, Inc.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Massey reports no disclosure.

Kimford J. Meador, MD, FAAN, FAES, FRCPE

Professor of Neurology and Neurological Sciences, Stanford University, Palo Alto, California

*Relationship Disclosure: Dr Meador receives research/grant support from Eisai Co, Ltd, and the National Institutes of Health/National Institute of Neurological Disorders and Stroke/National Institute of Child Health and Human Development (2U01-NS038455). Dr Meador’s institution receives financial support from The Epilepsy Study Consortium for his services as a consultant for Eisai Co, Ltd; GW Pharmaceuticals plc; NeuroPace, Inc; Novartis AG; Supernus Pharmaceuticals, Inc; Upsher-Smith Laboratories, LLC; UCB, Inc; and VIVUS LLC.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Meador reports no disclosure.

Eliza C. Miller, MD, MS

Assistant Professor of Neurology, Columbia University, New York, New York

*Relationship Disclosure: Dr Miller serves as a section editor for Stroke and receives research/grant support from the Gerstner Family Foundation, the National Institutes of Health/National Institute of Neurological Disorders and Stroke (K23NS107645, 1R01NS122815), and the National Institutes of Health/National Institute on Aging (R21AG069111). Dr Miller has served as an expert consultant for Argionis & Associates, LLC; Finch McCranie LLP; Grower, Ketcham, Edie, Telan & Meltz, PA; and Heyl, Royster, Voelker & Allen, PC.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Miller discusses the unlabeled/investigational use of recombinant tissue plasminogen activator for the treatment of acute ischemic stroke in pregnant women.

Heather E. Moss, MD, PhD, FAAN

Associate Professor of Ophthalmology, Neurology, and Neurological Sciences, Stanford University, Palo Alto, California

*Relationship Disclosure: Dr Moss has served on the editorial board of the Journal of Neuro-Ophthalmology and as an associate editor for Frontiers in Neurology and MedLink Neurology, an assistant editor for Frontiers in Ophthalmology, a review editor for Current Eye Research, a guest editor for Current Opinion in Neurology and Current Neurology and Neuroscience Reports, and a special issue editor for Life. Dr Moss has served as a consultant for Twenty/Twenty Therapeutics and Verana Health and on an advisory board for Genentech, Inc; has received personal compensation for speaking engagements for Vindico Medical Education; and receives research/grant support from the National Institutes of Health (P30 EY 026 877, R21 EY 031 726) and Research to Prevent Blindness.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Moss reports no disclosure.

Melissa Rayhill, MD, FAHS

Assistant Professor of Neurology, University at Buffalo Jacobs School of Medicine, State University of New York, Buffalo, New York

*Dr Rayhill has served as an associate editor of Headache: The Journal of Head and Face Pain.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Rayhill discusses the use of various medications for the treatment of headache in pregnancy and lactation, none of which are approved by the US Food and Drug Administration for use in pregnancy/lactation.

Rachel V. Rose, JD, MBA

Attorney, Rachel V. Rose Attorney at Law, PLLC; Affiliated Faculty, Baylor College of Medicine, Houston, Texas

*Relationship Disclosure: Ms Rose serves on the editorial board of BC Advantage and receives book royalties from the American Bar Association.
**Unlabeled Use of Products/Investigational Use Disclosure: Ms Rose reports no disclosure.

Janet F. R. Waters, MD, MBA, FAAN

Associate Professor of Neurology; Division Chief, Women’s Neurology, University of Pittsburgh Medical Center; Chief of Neurology, Magee-Women’s Hospital, Pittsburgh, Pennsylvania

*Relationship Disclosure: Dr Waters reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Waters reports no disclosure.

Self-Assessment and CME Test Writers

Nuri Jacoby, MD

Associate Professor of Neurology, SUNY Downstate Health Sciences University; Attending Neurologist, Maimonides Medical Center, Brooklyn, New York

*Relationship Disclosure: Dr Jacoby has received the Faculty Innovation in Education Award from the American Board of Psychiatry and Neurology.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Jacoby reports no disclosure.

Allison L. Weathers, MD, FAAN

Associate Chief Medical Information Officer, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

*Relationship Disclosure: Dr Weathers serves on the editorial board of Continuum and as chair of the adult neurosciences specialty steering board for Epic.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Weathers reports no disclosure.
All relevant financial relationships have been mitigated.